Medpace (NASDAQ:MEDP - Get Free Report) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share guidance of 12.260-13.040 for the period, compared to the consensus earnings per share estimate of 12.480. The company issued revenue guidance of $2.1 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.
Analyst Ratings Changes
A number of brokerages have recently commented on MEDP. Truist Financial cut their price target on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a report on Wednesday. Leerink Partnrs raised shares of Medpace to a "hold" rating in a report on Monday, March 24th. Robert W. Baird dropped their price objective on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a report on Wednesday. William Blair reiterated a "market perform" rating on shares of Medpace in a research note on Tuesday. Finally, TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and lowered their price target for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $349.30.
Get Our Latest Analysis on Medpace
Medpace Stock Performance
Medpace stock traded down $4.33 during trading hours on Friday, reaching $298.55. 399,606 shares of the company's stock traded hands, compared to its average volume of 339,939. Medpace has a fifty-two week low of $250.05 and a fifty-two week high of $459.77. The firm's 50 day moving average is $313.79 and its 200-day moving average is $331.70. The firm has a market capitalization of $9.02 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 3.81 and a beta of 1.46.
Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same period last year, the firm earned $3.20 earnings per share. Analysts predict that Medpace will post 12.29 EPS for the current year.
About Medpace
(
Get Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Recommended Stories
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
